Due Diligence and Custom Research: Preview Report
A free preview of how ProGen answers a commissioned question, from scope to verdict. It shows the five steps every commission follows, the twelve worked questions behind this offer across five sectors, four worked examples taken to a finding checked at the primary source, and the source register a buyer receives.
Commission your own question · Research cut-off: 18 November 2026

What this report answers
- How is a commissioned question scoped and broken into the parts a decision turns on?
- Which evidence answers each part, and how is every fact recorded?
- What kinds of decision does this cover, from investor diligence to market entry?
- What does a worked question return?
- What does a buyer receive, and how quickly is a commission scoped?
12 worked questions
Across five sectors and eleven kinds of decision, each taken to a finding checked at the primary source.
1 business day
To reply with the scope, the timeline and a fixed quotation.
What the analysis establishes
From question to verdict
Every commission follows five steps: scope, decompose, trace, record and answer. The question becomes the four to six parts the decision turns on, and each part goes to the evidence that answers it, from trial registries, regulator records, statute text, company filings and disclosures, to the read of the leaders running these businesses.
Twelve worked questions
Twelve realistic commissions across radiopharma, ADC, cell and gene therapy, CDMO and CRO, and eleven kinds of decision: investor and partner diligence, supply agreements, licensing, policy exposure, site selection, manufacturing, leadership, competitors, deals and market entry. Each reached a headline finding checked at the primary source.
Four worked examples
A policy question from an investor, a site selection question from a CRO, a supply question in cell therapy and a licensing question from a business development team. Each shows the question as commissioned, how it was decomposed, the evidence used, the headline finding with its source and date, a ProGen reading and what the full commission adds.
The record
Every fact is logged with its value, source and date. Interpretation is labeled "ProGen reading" and held apart from fact. Figures built from a reviewed set say so.
Built to your decision
Each commission is scoped to the decision in front of you: an investment, a partner, a supplier, a deal, a competitor or a market. We reply within one business day with the scope, the timeline and a fixed quotation.
About this intelligence
Sources include public registries, regulator records, statute text, company filings and disclosures. Other sources are proprietary ProGen intelligence sources. Facts are linked to their sources; interpretation is labeled "ProGen reading". Evidence is current to 18 November 2026.
Investors before an investment committee. Corporate development teams before a license, partnership or acquisition. Strategy teams entering a modality or a country. Supply and procurement teams qualifying a partner. Leadership teams preparing a board decision.
Contents
- Why commission a question
- The questions it answers
- How a question is answered
- Twelve worked questions
- Worked example 1: a policy question from an investor
- Worked example 2: a site selection question from a CRO
- Worked example 3: a supply question in cell therapy
- Worked example 4: a licensing question from a BD team
- The record
- What a buyer receives
- Scoping and turnaround
Sectors covered
Radiopharma, ADC, Cell and gene therapy, CDMO, CRO
The full 8-page briefing is free. Tell us where to send it and it downloads immediately.